IL196825A - Preparations and products containing the agonist irl-1620 for the receptor etb for use in the treatment of prostate cancer in combination with chemotherapy - Google Patents

Preparations and products containing the agonist irl-1620 for the receptor etb for use in the treatment of prostate cancer in combination with chemotherapy

Info

Publication number
IL196825A
IL196825A IL196825A IL19682509A IL196825A IL 196825 A IL196825 A IL 196825A IL 196825 A IL196825 A IL 196825A IL 19682509 A IL19682509 A IL 19682509A IL 196825 A IL196825 A IL 196825A
Authority
IL
Israel
Prior art keywords
articles
compositions
manufacture
treatment
combination
Prior art date
Application number
IL196825A
Other languages
English (en)
Hebrew (he)
Other versions
IL196825A0 (en
Inventor
Luigi Lenaz
Guru Reddy
Anil Gulati
Original Assignee
Spectrum Pharmaceuticals Inc
Luigi Lenaz
Guru Reddy
Univ Illinois
Anil Gulati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc, Luigi Lenaz, Guru Reddy, Univ Illinois, Anil Gulati filed Critical Spectrum Pharmaceuticals Inc
Publication of IL196825A0 publication Critical patent/IL196825A0/en
Publication of IL196825A publication Critical patent/IL196825A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL196825A 2006-08-02 2009-02-01 Preparations and products containing the agonist irl-1620 for the receptor etb for use in the treatment of prostate cancer in combination with chemotherapy IL196825A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/461,961 US20070032422A1 (en) 2002-10-24 2006-08-02 Methods, compositions and articles of manufacture for contributing to the treatment of cancers
PCT/US2007/074036 WO2008016793A2 (en) 2006-08-02 2007-07-20 Methods, compositions and articles of manufacture for contributing to the treatment of cancers

Publications (2)

Publication Number Publication Date
IL196825A0 IL196825A0 (en) 2011-08-01
IL196825A true IL196825A (en) 2015-08-31

Family

ID=38752363

Family Applications (1)

Application Number Title Priority Date Filing Date
IL196825A IL196825A (en) 2006-08-02 2009-02-01 Preparations and products containing the agonist irl-1620 for the receptor etb for use in the treatment of prostate cancer in combination with chemotherapy

Country Status (17)

Country Link
US (4) US20070032422A1 (cg-RX-API-DMAC10.html)
EP (2) EP2450037A1 (cg-RX-API-DMAC10.html)
JP (1) JP2009545609A (cg-RX-API-DMAC10.html)
KR (1) KR101507178B1 (cg-RX-API-DMAC10.html)
CN (1) CN101522186B (cg-RX-API-DMAC10.html)
AR (1) AR062177A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0715521A2 (cg-RX-API-DMAC10.html)
CA (1) CA2658340C (cg-RX-API-DMAC10.html)
DK (1) DK2046323T3 (cg-RX-API-DMAC10.html)
ES (1) ES2402232T3 (cg-RX-API-DMAC10.html)
IL (1) IL196825A (cg-RX-API-DMAC10.html)
MX (1) MX2009001233A (cg-RX-API-DMAC10.html)
NO (1) NO20090915L (cg-RX-API-DMAC10.html)
RU (1) RU2407527C2 (cg-RX-API-DMAC10.html)
TW (1) TWI469776B (cg-RX-API-DMAC10.html)
WO (1) WO2008016793A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200900017B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
ES2541657T3 (es) 2006-08-31 2015-07-23 Spectrum Pharmaceuticals, Inc. Sensibilización de células tumorales a terapia de radiación a través de la administración de agonistas de endotelina
PL2182977T3 (pl) * 2007-08-21 2017-01-31 Midwestern University Kompozycje do leczenia udaru lub incydentów mózgowo-naczyniowych za pomocą agonisty receptora endoteliny B
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
CA3023227C (en) * 2016-05-06 2021-11-02 Biodynamic Research Foundation Pharmaceutical composition containing macromolecular drug
WO2024222663A1 (zh) * 2023-04-26 2024-10-31 拜西欧斯（北京）生物技术有限公司 多肽及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550110A (en) 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
CA2135151A1 (en) 1993-11-08 1995-05-09 Mitsuhiro Wakimasu Cyclic hexapeptides, their production and use
US5811416A (en) 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
RU2180852C2 (ru) 1994-12-12 2002-03-27 Омерос Медикл Системс, Инк. Ингибирующий раствор и способ подавления боли, воспаления или спазма
US6251861B1 (en) 1996-06-27 2001-06-26 Takeda Chemical Industries, Ltd. Treatment of cerebral infarction using cyclic hexapeptides
EP0950418A2 (en) 1998-04-14 1999-10-20 Takeda Chemical Industries, Ltd. Composition for preventing or treating ischemic disease
PT1115391E (pt) 1998-09-25 2003-02-28 Warner Lambert Co Quimioterapia do cancro com acetildinalina em combinacao com gemcitabina capecitabina ou cisplatina
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
EP1289558A2 (en) 2000-05-31 2003-03-12 Warner-Lambert Company Llc Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
US6573285B2 (en) 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
CN1729012B (zh) * 2002-10-24 2013-05-22 伊利诺伊大学评议会 治疗实体瘤的组合物
US8217010B2 (en) * 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
WO2006057988A2 (en) 2004-11-22 2006-06-01 The Board Of Trustees Of The University Of Illinois Use of endothelin etb receptor agonists and eta receptor antagonists in tumor imaging
CA2598439A1 (en) * 2005-02-22 2006-08-31 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
ES2541657T3 (es) 2006-08-31 2015-07-23 Spectrum Pharmaceuticals, Inc. Sensibilización de células tumorales a terapia de radiación a través de la administración de agonistas de endotelina

Also Published As

Publication number Publication date
ZA200900017B (en) 2009-11-25
RU2009107085A (ru) 2010-09-10
HK1129601A1 (en) 2009-12-04
IL196825A0 (en) 2011-08-01
MX2009001233A (es) 2009-02-12
EP2046323B1 (en) 2013-02-13
US20130102543A1 (en) 2013-04-25
US20090155206A1 (en) 2009-06-18
EP2450037A1 (en) 2012-05-09
TW200820965A (en) 2008-05-16
NO20090915L (no) 2009-02-27
EP2046323A2 (en) 2009-04-15
CN101522186A (zh) 2009-09-02
US8030278B2 (en) 2011-10-04
DK2046323T3 (da) 2013-04-22
AR062177A1 (es) 2008-10-22
US20110315575A1 (en) 2011-12-29
US20070032422A1 (en) 2007-02-08
WO2008016793A2 (en) 2008-02-07
US8440620B2 (en) 2013-05-14
US8729023B2 (en) 2014-05-20
CN101522186B (zh) 2013-06-05
CA2658340A1 (en) 2008-02-07
KR20090034355A (ko) 2009-04-07
KR101507178B1 (ko) 2015-03-30
BRPI0715521A2 (pt) 2013-06-25
JP2009545609A (ja) 2009-12-24
ES2402232T3 (es) 2013-04-30
TWI469776B (zh) 2015-01-21
RU2407527C2 (ru) 2010-12-27
CA2658340C (en) 2015-11-24
WO2008016793A3 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
GB2453011B (en) Antifolate agent compositions in the treatment of cancer
IL200755A (en) Use of nanoparticles containing rapamycin and albumin to create a dosage unit cancer drug preparation and kit containing them
PL2076565T3 (pl) Kompozycje polietylenowe, sposoby ich wytwarzania i wytworzone z nich wyroby
PL2087089T3 (pl) Cząstki zawierające korzystny czynnik
IL206148A0 (en) Polymeric composition, method for the manufacture of the polymeric composition, articles based on this polymeric composition and use of these articles
ZA200808900B (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
IL208937A0 (en) Cell binding agent cytotoxic drug conjugates, compositions comprising the same and uses thereof
IL200846A0 (en) Oligomer-protease inhibitor conjugates, compositions comprising the same and uses thereof
EP2046258A4 (en) LUBRICATING COMPOSITIONS AND ARTICLES THEREOF
IL208451A0 (en) Pharmaceutical compositions comprising a chemotherapeutic agent and an anti-glypican 3 antibody for use in treating hepatic cancer
EP2064709A4 (en) COMPRESSED CONDUCTIVE MATERIALS AND ARTICLES MANUFACTURED THEREFROM
ZA200900794B (en) Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
EP1997824B8 (en) Perfluoropolyether-modified aminosilane, surface treating agent, and aminosilane-coated article
IL200847A (en) Oligomer-antihistamine couplings, preparations containing them and their uses
GB0618963D0 (en) Formulations and composites with reactive fillers
EP2085425A4 (en) RESIN COMPOSITION FOR ELECTRIC METAL SEPARATION, FORM BODY AND METAL-COATED MOLDED BODY
IL194447A0 (en) Coating compositions, articles, and methods of coating articles
EP2251929A4 (en) WIDE BAND ANTENNA, AND CLOTHES AND ARTICLES USING SAME
IL205966A0 (en) Oligomer-tricyclic conjugates, compositions comprising the same and uses thereof
IL198245A0 (en) Self designed fashion wear and other articles
IL206060A0 (en) Conjugates of anti-rg-1 antibodies, compositions comprising the same and uses thereof
IL194581A (en) Procindiphosphines, a process for their preparation, complexes of transition metals containing them, and uses in the preparation of organic compounds
ZA200903172B (en) Benefit agent-containing delivery particle
GB0821171D0 (en) Radiation absorbing compositions, methods and articles incorporating such compositions
IL197920A0 (en) Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees